Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Amgen, AstraZeneca, Novartis Pharmaceuticals Corporation,
Sanofi, and Turning Point Therapeutics
Description:
Lung cancer is the second most common cancer in both men and women,
according to the American Cancer Society. It accounts for about 15%
of all new cancers, and during 2021, it was expected that there were
about 228,820 new cases of lung cancer. Non small-cell lung cancer (NSCLC)
accounts for approximately 80% of all lung cancer cases. Lung cancer
is by far the leading cause of cancer death among both men and
women, and there were an estimated 135,720 deaths from lung cancer
in 2021, accounting for around 29% of all cancer deaths. More people
die of lung cancer than of colon, breast, and prostate cancers
combined. As more comprehensive information has been gathered
regarding tumor characterization, treatment modalities for NSCLC
have expanded to include agents with more specific targets. The use
of histologic subtypes and molecular biomarker assessment in NSCLC
has resulted in therapeutic paradigms that can be optimized for
individual patients based on unique characteristics of their cancer.
Healthcare professionals (HCPs) need to be aware of information
regarding tumor-specific diagnosis, expanding treatment options, and
supporting data to maximize the care of their patients. With so many
effective treatment options becoming available, it is critical to
inform medical directors, oncologists and nurses about these agents,
and strategies to effectively manage NSCLC patients.
Upon completion of this
activity, participants will be able to:
-
Examine the clinical and economic
burden of non-small cell lung cancer (NSCLC), including factors
that contribute to poor prognosis and increased costs
-
Analyze recent clinical trial data
and information on the efficacy, safety and mechanisms of action
of new and emerging therapies for the treatment of advanced
NSCLC
-
Assess the role of ROS1 tyrosine
kinase inhibitors in the treatment of patients with advanced
NSCLC
-
Explore the unique adverse events
among novel therapies in advanced NSCLC and explore
evidence-based strategies to ensure the timely recognition and
proper management of these adverse events
-
Discuss the managed care
considerations of current and emerging tyrosine kinase
inhibitors by exploring where these agents may fit into current
advanced NSCLC management paradigm
|
Faculty: |
Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Matthew Gubens, MD, MS has served as a consultant and
contributed to ad boards for AstraZeneca, BMS, Cardinal
Health, Genentech/Roch, Genzyme/Sanofi, Guardant, iTeos,
and Surface. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
Amgen, AstraZeneca, Novartis Pharmaceuticals Corporation,
Sanofi, and Turning Point Therapeutics
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |